Infertility caused by intrauterine adhesions (IUA), also known as Asherman’s syndrome, has long been a clinical challenge with limited effective treatments. A new study led by researchers at Guangzhou Medical University in China offers a potential breakthrough: a regenerative gel that can restore uterine health and fertility.
The research, published in Advanced Healthcare Materials, demonstrates that an injectable hydrogel containing either stem cells or their bioactive byproducts can repair damaged uterine tissue, prevent scar tissue from reforming, and successfully support pregnancy in animal models.
The Challenge of Uterine Scarring
Intrauterine adhesions occur when scar tissue forms inside the uterus, often as a result of surgeries such as D&C procedures following miscarriage or childbirth, or due to infections. This scar tissue can cause the front and back walls of the uterus to stick together, leading to severe consequences:
- Menstrual irregularities: Lighter periods or complete absence of menstruation.
- Pain: Chronic pelvic pain.
- Infertility: Difficulty conceiving or recurrent miscarriages.
While Asherman’s syndrome is relatively rare—affecting approximately 1–5 per 10,000 women—it is frequently underdiagnosed. Current standard care involves surgical separation of the adhesions. However, this approach has a significant drawback: the adhesions often return.
“It is much like a wound that keeps scarring over,” explains Professor Zhiyong Zhang from the Translational Research Centre of Regenerative Medicine and 3D Printing at Guangzhou Medical University. “Severe intrauterine adhesions are a major cause of infertility, yet the condition currently lacks a safe and effective treatment.”
A Dual-Action Regenerative Gel
To address this recurring issue, Zhang and his team developed a novel therapeutic approach using a clinical-grade, injectable fibrin hydrogel called Porcine Fibrin Sealant (PFS). This gel serves two critical functions:
- Physical Barrier: It acts as a spacer to prevent the uterine walls from adhering to each other during the healing process.
- Biological Catalyst: It delivers repair signals that stimulate the regeneration of damaged endometrial tissue.
Stem Cells as Repair Agents
The initial phase of the study focused on mesenchymal stem cells (MSCs), which are multipotent cells found in tissues such as bone marrow, fat, umbilical cord, and placenta. MSCs are known for their ability to reduce inflammation, promote blood vessel growth, and improve the local healing environment.
The researchers embedded MSCs derived from human umbilical cords into the PFS hydrogel. Under microscopic analysis, the gel maintained a porous 3D network that allowed for nutrient exchange and cell migration, ensuring the stem cells remained viable and active within the matrix.
When tested on animal models with induced intrauterine adhesions, the results were significant:
- Tissue Restoration: Only the group treated with the stem-cell-infused gel (PFS-MSC) achieved near-complete restoration of endometrial thickness and gland numbers.
- Reduced Fibrosis: There was a marked decrease in scar tissue formation.
- Functional Recovery: Treated animals showed improved embryo implantation rates. By day 18 of pregnancy, fetal development in treated uteri was comparable to that in healthy tissue. Crucially, the treatment resulted in the birth of healthy offspring, proving that reproductive capacity was fully restored.
From Living Cells to Cell-Free Therapy
While the stem cell therapy was effective, the researchers identified a major hurdle for clinical translation: the complexity and potential risks associated with using living cells in patients. To simplify the treatment and enhance safety, the team explored a cell-free alternative.
They replaced the living stem cells with extracellular vesicles (EVs). EVs are tiny, lipid-bound particles naturally secreted by cells. They act as biological messengers, carrying proteins, RNA, and other biomolecules that coordinate tissue repair without the need for live cells.
The findings were surprising. The cell-free hydrogel (PFS-EVs) achieved therapeutic outcomes nearly identical to those of the stem cell treatment.
“[EVs] achieved almost the same therapeutic effect as the mesenchymal stem cells themselves,” says Zhang. “The idea of turning a cell-based therapy into a cell-free product could significantly reduce the complexity and risk of future clinical use, and in doing so, make the treatment more accessible to a wider range of patients.”
Future Directions and Clinical Implications
Although no EV-based therapy has yet been approved for human use, this study marks a significant shift in treating uterine infertility. The focus is moving from merely removing scar tissue to systemically rebuilding a healthy uterine environment.
Key Advantages of the Cell-Free Approach
- Safety: Eliminates risks associated with live cell transplantation, such as immune rejection or uncontrolled cell growth.
- Simplicity: Easier to store, transport, and administer.
- Precision: Potential to identify specific RNA or proteins within EVs that drive repair, allowing for the design of next-generation drugs with greater potency.
Preventive Potential
Beyond treating existing adhesions, the gel could serve as a preventive measure. Zhang suggests that applying the hydrogel immediately after routine uterine surgeries could prevent adhesions from forming in the first place, thereby protecting fertility proactively.
Conclusion
The development of this regenerative gel represents a promising step forward for women suffering from infertility due to intrauterine adhesions. By leveraging the power of stem cell-derived vesicles, researchers have created a safe, effective, and potentially scalable treatment that not only repairs physical damage but restores full reproductive function. As the field advances, overcoming manufacturing hurdles will be key to bringing this therapy from the lab to the clinic.
